TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24993861

Group type: EXPERIMENTAL
Intervention: Passive leg raise (PLR) during CPR
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Flat position during CPR
Number of subjects: 3000
Study: 22848157

Group type: EXPERIMENTAL
Intervention: COPD-PS plus copd-6
Number of subjects: 9704

Group type: EXPERIMENTAL
Intervention: COPD-PS alone
Number of subjects: 9704

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 9704
Study: 20012446

Group type: EXPERIMENTAL
Intervention: Alcohol beverage (1 g of ethanol per kg bodyweight; vodka and orange juice)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-alcoholic beverage (orange juice)
Number of subjects: 10
Study: 18281661

Group type: EXPERIMENTAL
Intervention: Sentinel node dissection only
Number of subjects: 403

Group type: COMPARATOR
Intervention: Sentinel node dissection
Number of subjects: 403
Study: 15801939

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg bid for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no diltiazem)
Number of subjects: 20
Study: 12566365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Probucol 500 mg BID
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: AGI‐1067 70 mg once daily
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: AGI‐1067 140 mg once daily
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: AGI‐1067 280 mg once daily
Number of subjects: 305
Study: 10652637

Group type: EXPERIMENTAL
Intervention: Experimental group received verbal instructions with visual and auditory feedback during training sessions.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group received visual cueing about stance equilibrium and dynamic perturbations.
Number of subjects: 11
Study: 9110190

Group type: EXPERIMENTAL
Intervention: Computer display of high frame rate digital cineloops (47 frames/s)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Computer display of lower frame rate digital cineloops (24 frames/s)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Videotape recordings
Number of subjects: 25
Study: 8374931

Group type: EXPERIMENTAL
Intervention: sotalol (320 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: sotalol
Number of subjects: 30
Study: 3534803

Group type: EXPERIMENTAL
Intervention: DHE 0.5 mg plus heparin 5000 U
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: DHE 0.5 mg plus heparin 2500 U
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Heparin 5000 U
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: DHE 0.5 mg
Number of subjects: 888

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 888
Study: 30079962

Group type: EXPERIMENTAL
Intervention: NHO‐style vocal hygiene educational program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control education program
Number of subjects: 200
Study: 27181342

Group type: EXPERIMENTAL
Intervention: Combination of Ananas comosus extract and honey (Bromelin®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Honey alone (placebo group)
Number of subjects: 0
Study: 24509551

Group type: EXPERIMENTAL
Intervention: Bidirectional needle rotation at LI10
Number of subjects: 22

Group type: COMPARATOR
Intervention: Mock rotation at LI10
Number of subjects: 22
Study: 22732831

Group type: EXPERIMENTAL
Intervention: Pancreatic duct stent (PDS)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Guidewire (PDW)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both PDS and PDW
Number of subjects: 87
Study: 19608290

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 970
Study: 18690309

Group type: EXPERIMENTAL
Intervention: Tramadol 50mg (group T50)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tramadol 100mg (group T100)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotonic saline (control group)
Number of subjects: 60
Study: 15965321

Group type: EXPERIMENTAL
Intervention: Integrated PET-CT imaging
Number of subjects: 173

Group type: COMPARATOR
Intervention: CT with contrast
Number of subjects: 173
Study: 14964319

Group type: EXPERIMENTAL
Intervention: Remote audiometer operated via the Internet
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional audiometer
Number of subjects: 45
Study: 10474558

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention over approximately 20 months
Number of subjects: 2519

Group type: COMPARATOR
Intervention: Delayed intervention (no program until after the follow-up survey)
Number of subjects: 2519
Study: 8743353

Group type: COMPARATOR
Intervention: Microsurgical epididymal sperm aspiration (MESA) with ICSI; 29 cycles performed on 25 couples.
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Epididymal micropuncture with nerve stimulation with ICSI; 30 cycles performed on 28 couples.
Number of subjects: 53
Study: 8101584

Group type: EXPERIMENTAL
Intervention: Morphine in 5% dextrose (100 micrograms/kg per h for 2 h followed by 25 micrograms/kg per h continuous infusion)
Number of subjects: 41

Group type: COMPARATOR
Intervention: 5% dextrose (placebo)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Morphine and placebo
Number of subjects: 41
Study: 2943812

Group type: EXPERIMENTAL
Intervention: Two doses of 5 micrograms of hepatitis B recombinant DNA yeast vaccine (H‐B‐VAX II) at 0 and 1 month (Group I)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Three doses of 5 micrograms of hepatitis B recombinant DNA yeast vaccine (H‐B‐VAX II) at 0, 1 and 6 months (Group II)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Three doses of 10 micrograms of plasma‐derived hepatitis B vaccine (H‐B‐VAX) (Group III)
Number of subjects: 141
Study: 30253879

Group type: EXPERIMENTAL
Intervention: Resolute Onyx stent
Number of subjects: 2488

Group type: COMPARATOR
Intervention: Orsiro stent
Number of subjects: 2488
Study: 25185863

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO) for 5 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non-HFCWO (control)
Number of subjects: 43
Study: 24875092

Group type: EXPERIMENTAL
Intervention: Quidel Influenza A+B POCT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Viral culture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BinaxNOW pneumococcal POCT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sputum culture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall pooled estimates of sensitivity and specificity of POCTs for influenza
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional viral culture
Number of subjects: 0
Study: 22587925

Group type: EXPERIMENTAL
Intervention: Heparin infusion at 18 U×kg(‐1)×h(‐1) for 24 hours (Group A)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Intravenous drip of 12,500 U of heparin once a day (Group B)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin calcium injection twice a day (Group C)
Number of subjects: 351
Study: 20660970

Group type: EXPERIMENTAL
Intervention: 2% sodium fluoride iontophoresis
Number of subjects: 30

Group type: COMPARATOR
Intervention: varnish
Number of subjects: 30

Group type: COMPARATOR
Intervention: adhesive bonded liner
Number of subjects: 30
Study: 18320208

Group type: EXPERIMENTAL
Intervention: Maltodextrin plus hydrolyzed whey protein enriched with 175 mg of glutamine dipeptide (MGln)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 9
Study: 15640998

Group type: EXPERIMENTAL
Intervention: Shoulder ROM assessment (manual measurement)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Shoulder ROM assessment (digital analysis)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both methods of shoulder ROM assessment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prevalence of shoulder contractures in patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prevalence of shoulder contractures in all shoulder joints
Number of subjects: 50
Study: 12733728

Group type: EXPERIMENTAL
Intervention: Gross motor activities (30 minutes/day, 5 days/week for 12 months) with calcium (1000 mg/day)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Fine motor activities (30 minutes/day, 5 days/week for 12 months) with calcium (1000 mg/day)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Gross motor activities (30 minutes/day, 5 days/week for 12 months) with placebo
Number of subjects: 239

Group type: COMPARATOR
Intervention: Fine motor activities (30 minutes/day, 5 days/week for 12 months) with placebo
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg/day)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 10569535

Group type: EXPERIMENTAL
Intervention: Ureteroscopy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy
Number of subjects: 80
Study: 8939828

Group type: EXPERIMENTAL
Intervention: Preoperative ERC with ESE followed by LC during the same hospital admission (Group A)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Single stage laparoscopic management (Group B) consisting of LC and laparoscopic stone extraction (trans-cystic duct route or direct supraduodenal common duct exploration)
Number of subjects: 207
Study: 1748336

Group type: EXPERIMENTAL
Intervention: Alfentanil, up to 0.025 mg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fentanyl, 0.0025 mg/kg
Number of subjects: 36
Study: 7019841

Group type: EXPERIMENTAL
Intervention: Indomethacin treatment (0.2 mg/kg enteral indomethacin, three doses at eight-hour intervals in phase 2)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Indomethacin treatment (0.2 mg/kg enteral indomethacin, three doses at 24-hour intervals in phase 1)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Indomethacin treatment (phase 2)
Number of subjects: 39
Study: 30747612

Group type: EXPERIMENTAL
Intervention: Utility-weighted modified Rankin Scale (UW-mRS)
Number of subjects: 2030

Group type: EXPERIMENTAL
Intervention: AQoL‐4D
Number of subjects: 2030

Group type: EXPERIMENTAL
Intervention: Time post-stroke
Number of subjects: 2030

Group type: EXPERIMENTAL
Intervention: Derivation method
Number of subjects: 2030
Study: 31533735

Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) algorithm
Number of subjects: 184
Study: 26016655

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus CNCM I‐4036
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei CNCM I‐4034
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve CNCM I‐4035
Number of subjects: 0
Study: 24502311

Group type: EXPERIMENTAL
Intervention: 2% methylene blue aqueous solution irradiated with light emission diode device (MBLED/PDT) with 18 J/cm(2) and placebo capsule per week
Number of subjects: 80

Group type: COMPARATOR
Intervention: 300 mg oral fluconazole per week and placebo PDT (haematoxylin-diluted 1:10)
Number of subjects: 80
Study: 23515202

Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide 20mg (1ml)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 188
Study: 19996072

Group type: EXPERIMENTAL
Intervention: Perihematomal edema growth
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Baseline hematoma volume
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 404
Study: 18036291

Group type: EXPERIMENTAL
Intervention: Adenosine infusion (initial rate 50 microg.kg(‐1).min(‐1) increasing to 150 microg.kg(‐1).min(‐1) over 10 minutes)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 40
Study: 14758947

Group type: EXPERIMENTAL
Intervention: Scheduled regimen of minor oral analgesic medications (acetaminophen [10 mg/kg] and ibuprofen [10 mg/kg] alternating every 2 hours)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Analgesic medication when requested (Control Group B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Scheduled regimen of minor oral analgesic medications
Number of subjects: 50
Study: 11453909

Group type: EXPERIMENTAL
Intervention: Active treatment group (allergen‐impermeable mattress encasing, acaricide spray containing tannic acid and benzylbenzoate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (allergen‐permeable encasing, spray containing water and traces of ethanol)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active treatment group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 9445185

Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Echinomycin
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Trimetrexate
Number of subjects: 136
Study: 8111718

Group type: EXPERIMENTAL
Intervention: DTIC 650 mg/m2
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: DTIC 850 mg/m2
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: DTIC (combined low and high doses)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 63
Study: 3183054

Group type: EXPERIMENTAL
Intervention: Pentazocine with low-dose naloxone
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Morphine with low-dose naloxone
Number of subjects: 105
Study: 30755164

Group type: EXPERIMENTAL
Intervention: Full dose (11.4 mg betamethasone)
Number of subjects: 3142

Group type: COMPARATOR
Intervention: Half dose (placebo)
Number of subjects: 3142
Study: 28672376

Group type: EXPERIMENTAL
Intervention: Phoneme Factory Sound Sorter software administered by educators over 9 weeks
Number of subjects: 123

Group type: COMPARATOR
Intervention: Typical classroom practices
Number of subjects: 123
Study: 25326216

Group type: EXPERIMENTAL
Intervention: One cycle treatment (group A)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Two cycle treatment (group B)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 409
Study: 24121100

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (12 weekly group sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention retraining intervention for social anxiety disorder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control condition
Number of subjects: 0
Study: 21052978

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 9795

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9795
Study: 17952446

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 45
Study: 17167846

Group type: EXPERIMENTAL
Intervention: Listening to music (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No music (Group 2)
Number of subjects: 60
Study: 14501608

Group type: EXPERIMENTAL
Intervention: 0.5 mg E2 + 25 g SPI with 120 mg isoflavones
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 1.0 mg E2 + 25 g SPI with 120 mg isoflavones
Number of subjects: 39

Group type: COMPARATOR
Intervention: 0.5 mg E2 + placebo
Number of subjects: 39

Group type: COMPARATOR
Intervention: 1.0 mg E2 + placebo
Number of subjects: 39
Study: 11103750

Group type: EXPERIMENTAL
Intervention: Intravenous cyclosporine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral cyclosporine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bioavailability of cyclosporine
Number of subjects: 22
Study: 8730315

Group type: EXPERIMENTAL
Intervention: Oral artesunate (100 mg single dose on day 1 followed by 50 mg twice daily for 5 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral artemisinin (500 mg single dose on day 1 followed by 250 mg twice daily for 4 days and another 500 mg single dose on day 6)
Number of subjects: 40
Study: 1328022

Group type: EXPERIMENTAL
Intervention: Older Alcoholic Rehabilitation (OAR) program
Number of subjects: 137

Group type: COMPARATOR
Intervention: Traditional care program
Number of subjects: 137
Study: 3698064

Group type: EXPERIMENTAL
Intervention: TheoDur
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Respbid
Number of subjects: 13

Group type: COMPARATOR
Intervention: TheoDur and Respbid
Number of subjects: 13
Study: 31215320

Group type: EXPERIMENTAL
Intervention: Case-based learning (CBL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional lecture-based teaching method
Number of subjects: 80
Study: 29194339

Group type: EXPERIMENTAL
Intervention: 1:1:1 plasma-platelet-red blood cell ratios
Number of subjects: 454

Group type: COMPARATOR
Intervention: 1:1:2 plasma-platelet-red blood cell ratios
Number of subjects: 454
Study: 26688463

Group type: EXPERIMENTAL
Intervention: Oral herbs (n=35)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo treatment (n=32)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Post-salvage therapy comparison
Number of subjects: 67
Study: 24648131

Group type: EXPERIMENTAL
Intervention: Pre-procedure ultrasound
Number of subjects: 606

Group type: COMPARATOR
Intervention: Landmark methods (Pathfinder)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Landmark methods (Direct Cannulation)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Pre-procedure ultrasound (inexperienced operators)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Landmark methods (experienced operators)
Number of subjects: 606
Study: 22445187

Group type: EXPERIMENTAL
Intervention: Oxygen group (100% oxygen at 2l/min via nasal cannula for at least 30 min before delivery)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Room Air group (connected to nasal cannula while on room air)
Number of subjects: 56
Study: 20573752

Group type: EXPERIMENTAL
Intervention: Elevated A1C (5.7-6.4%)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerance (IGT)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Impaired Fasting Glucose (IFG)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Intermediate and diabetic range of 2-h glucose
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Diabetic A1C levels in women
Number of subjects: 593
Study: 17459139

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation delivered by practice nurses
Number of subjects: 19
Study: 15892437

Group type: EXPERIMENTAL
Intervention: 3-drug regimen of indinavir + zidovudine (or stavudine) + lamivudine
Number of subjects: 1178

Group type: COMPARATOR
Intervention: 2-drug combination of zidovudine (or stavudine) + lamivudine
Number of subjects: 1178
Study: 12878621

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 500
Study: 10562783

Group type: EXPERIMENTAL
Intervention: Opioid-free epidural-spinal anaesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anaesthesia with continuous epidural bupivacaine 15 mg h‐1 or bupivacaine 10 mg h‐1 with epidural morphine 0.2 mg h‐1
Number of subjects: 40
Study: 8721469

Group type: EXPERIMENTAL
Intervention: DMSO 50% in a fatty cream (group A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 32
Study: 1676358

Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 0.6% metipranolol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 2% butylamino-phenoxy-propanol-acetate (BPPA)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1% timolol
Number of subjects: 28
Study: 6841664

Group type: EXPERIMENTAL
Intervention: Loprazolam (0.5, 1.0, and 1.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam (10, 20, and 30 mg)
Number of subjects: 0
Study: 30753648

Group type: COMPARATOR
Intervention: 5 nights of continuous 6.5-hour time-in-bed (TIB)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 5-hour nocturnal TIB with a 1.5-hour afternoon nap (split sleep)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both sleep-restricted groups (split and continuous sleep)
Number of subjects: 58
Study: 30413417

Group type: EXPERIMENTAL
Intervention: Stepped wedge cluster randomised trial (SW‐CRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CONSORT statements for individual and cluster randomised trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reporting items with explanations and examples
Number of subjects: 0
Study: 26189570

Group type: EXPERIMENTAL
Intervention: Intramuscular paliperidone palmitate 3-month (PP3M) formulation (75-525 mg eq)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Intramuscular paliperidone immediate release (IR) (1 mg)
Number of subjects: 328
Study: 24263659

Group type: EXPERIMENTAL
Intervention: 3 g of L-carnitine (LK-3)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 4 g of L-carnitine (LK-4)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (P-3 and P-4)
Number of subjects: 26
Study: 21820871

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 322
Study: 20802094

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 97

Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 97
Study: 16714323

Group type: EXPERIMENTAL
Intervention: Psilocybin (medium dose: 115 microg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Psilocybin (high dose: 250 microg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Psilocybin (medium and high doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15288990

Group type: EXPERIMENTAL
Intervention: Dolasetron (12.5 mg)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Droperidol (10 microg. kg(‐1))
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Combination of droperidol and dolasetron
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 304
Study: 11751803

Group type: EXPERIMENTAL
Intervention: Home telemedicine unit providing synchronous videoconferencing with a project-based nurse, electronic transmission of home fingerstick glucose and blood pressure data, and Web access to a project Web site.
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 1500
Study: 9817708

Group type: EXPERIMENTAL
Intervention: Nebulized 500 micrograms ipratropium bromide (IB)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline placebo (P)
Number of subjects: 29
Study: 7714223

Group type: EXPERIMENTAL
Intervention: MDL 11,939, 32 mg thrice daily
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72